Tumor-associated macrophage

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Tumor-associated macrophage, Research, Annual general meeting, Renal cell carcinoma, Hereditary diffuse gastric cancer, Head, Colorectal cancer, ESMO, Administration, Patient, Triple-negative breast cancer, ASCO, MSK, FDA, Lung cancer, G&A, Immunotherapy, Patent, ORR, Ovarian cancer, MPH, Cancer, Trial of the century, Diagnosis, Nivolumab, SITC, Operation, Antibody, Research and development, R, Congress, Orphan, Society, TNBC, ISAC, NSCLC, Pharmaceutical industry, Vaccine, Cryptocurrency

Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.

Key Points: 
  • Collaboration Revenue – Collaboration revenue was $2.5 million for the quarter ended September 30, 2023, compared to $2.1 million for the same quarter in 2022.
  • Research and Development (R&D) Expenses – R&D expenses were $15.0 million for the quarter ended September 30, 2023, compared to $19.0 million for the same quarter in 2022.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.8 million for the quarter ended September 30, 2023, compared to $5.5 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.2 million for the quarter ended September 30, 2023, compared to $22.3 million for the same quarter in 2022.

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

Retrieved on: 
Saturday, December 9, 2023
Oncology, Health, Genetics, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Tumor-associated macrophage, Associate, Toxicity, Weill Cornell Medicine, Progression-free survival, ASH, IND, Immunosuppression, Clinical trial, B-cell lymphoma, Patient, Tumor microenvironment, Pediatric Hematology and Oncology, Pharmacology, Lymph, Lymphatic system, TME, Therapy, Cancer, CD47, CMO, Drug resistance, 65th Street Yard, Doctor of Philosophy, Chemokine, Society, Overalls, Pharmaceutical industry, Vaccine, DLBCL, Hematology, Lymphoma, MD

Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

Key Points: 
  • Scenic Biotech , a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.
  • The new preclinical data covers results for SC-2882, Scenic’s first-in-class QPCTL inhibitor, as a potential new treatment approach for diffuse large B-cell lymphoma (DLBCL).
  • SC-2882 targets QPCTL and thereby inhibits the CD47-SIRPα “don’t eat me” checkpoint and lowers immune suppression in the tumor microenvironment.
  • Analysis of DLBCL patient datasets revealed that QPCTL expression negatively correlates with overall and progression-free survival.

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

Retrieved on: 
Monday, December 18, 2023
Georgetown University, Tumor-associated macrophage, AMES, Research, GLP, Safety, Therapy, Incidence, RECIST, Toxicology, IND, Risk, Macrophage, Patient, FIH, PFS, MD Anderson Cancer Center, U.S. FDA, FDA, Pembrolizumab, Animal, ICB, SAB, Pharmacokinetics, Marketing, Investigational New Drug, FAAAS, Progression-free survival, ORR, MD, Cancer, MTD, Phase, Doctor of Philosophy, HDAC6, Biomarker, Infrared spectroscopy correlation table, Immunotherapy, Coronavirus Scientific Advisory Board, Neoplasm, Rat, Dog, Government, Pharmaceutical industry, Medicine

AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.

Key Points: 
  • AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.
  • "The FDA clearance of our IND for AVS100 marks an amazing step for our company towards the fulfillment of our mission.
  • "FDA clearance of our IND for AVS100 represents a significant milestone for Avstera's mission in providing state of the art oncological agents to tackle solid tumors.
  • Undoubtedly, the IND approval of AVS100 selective HDAC6 inhibitor will open new opportunities to potentially enhance response rates for patients."

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

Retrieved on: 
Tuesday, October 17, 2023
Cancer, Pharmacokinetics, NSCLC, Trial of the century, Triple-negative breast cancer, Lung cancer, Safety, Ovarian cancer, Immunotherapy, Tumor-associated macrophage, Clinical trial, Colorectal cancer, Head, TNBC, Renal cell carcinoma, Patient, Tams, Vaccine, Pharmaceutical industry

The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), or ovarian cancer.

Key Points: 
  • The study will evaluate BDC-3042 in patients with metastatic or unresectable triple-negative breast cancer (TNBC), colorectal cancer, clear cell renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), or ovarian cancer.
  • “We are excited to have dosed the first patient in this first-in-human clinical trial, which will evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of BDC-3042 in a diverse set of advanced cancers,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
  • “BDC-3042 is a monoclonal antibody that repolarizes tumor-associated macrophages (TAMs) to attack tumor cells and is the first-in-class Dectin-2 agonist.
  • “In preclinical studies, BDC-3042 has shown the ability to repolarize TAMs from a tumor-supportive to a tumor-destructive phenotype.”

The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Sparx, ASX, SPARX Group, Cell, Therapy, Myeloid-derived suppressor cell, Cytokine release syndrome, Mab, Safety, Hereditary diffuse gastric cancer, Tumor-associated macrophage, GC, MDSC, CD1D, Cancer, Tams, Fatality, Vaccine, Pharmaceutical industry

Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.

Key Points: 
  • Dr. Gui-Dong Zhu, CEO of the SparX Group, elucidated on the significance of this collaboration: "Our partnership with Arovella represents a transformative phase in advancing mAb-based therapies.
  • Invariant Natural Killer T (iNKT) cells, distinguished by their recognition of lipid antigens via the CD1d molecule, have emerged as potent therapeutic vectors.
  • We profoundly acknowledge CLDN 18.2-iNKT cell therapy as a groundbreaking paradigm in oncological therapeutics."
  • The pathological architecture of tumor development often exposes the CLDN18.2, rendering it accessible to novel treatments such as CAR-iNKT cell therapies.

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Retrieved on: 
Monday, September 18, 2023
Oncology, FDA, Health, Genetics, Pharmaceutical, Biotechnology, Tumor-associated macrophage, Type 2 diabetes, R&D, Drug development, Clinical trial, Cancer, Toxicity, Type 2, Monocyte, Patient, Disease, Toxic epidermal necrolysis, Mortality, CD4, Metastasis, Safety, Pharmaceutical industry, IND

KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing first-in-class, oral, small molecule inhibitors of the retinoid pathway, today announces that it has selected KAYO-1609 as its first drug development candidate.

Key Points: 
  • KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing first-in-class, oral, small molecule inhibitors of the retinoid pathway, today announces that it has selected KAYO-1609 as its first drug development candidate.
  • With the nomination of KAYO-1609 as the development candidate, KayoThera is well-positioned for IND-enabling studies, clinical planning, and partnering activities.
  • Retinoid signaling further forces differentiation of monocytes into tumor-associated macrophages that can promote tumor growth and metastasis.
  • We are committed to developing retinoid signaling pathway inhibitors as novel therapeutic modalities that can improve outcomes for patients living with these and other serious diseases.”

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

Retrieved on: 
Tuesday, September 12, 2023
Patent, Tumor-associated macrophage, Cancer, Antibody, Pharmaceutical industry

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042.

Key Points: 
  • REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042.
  • The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023.
  • “The issuance of this patent is an important milestone in protecting the composition of matter and methods of treatment for our BDC-3042 clinical candidate,” explained Justin A. Kenkel, Ph.D., BDC-3042 co-inventor and Principal Scientist at Bolt Biotherapeutics.
  • “This patent covers antibodies with a novel mechanism of action that leverages Dectin-2 agonism to repolarize tumor-associated macrophages into immunostimulatory, anti-tumor macrophages.

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023
Memorial Sloan Kettering Cancer Center, Tumor-associated macrophage, Operation, PRS, PD, ESMO, Clinical trial, Cancer, G&A, Tams, Immunotherapy, Trial of the century, ASCO, ISAC, Patient, Administration, Annual general meeting, MSK, Research and development, R, Research, FDA, MPH, IND, Society, Conference, Nivolumab, Pharmaceutical industry, Vaccine, Cryptocurrency, Doctor of Philosophy

REDWOOD CITY, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided an update on the continued advancement of its clinical programs.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2023 and provided an update on the continued advancement of its clinical programs.
  • This is our second successful IND and we expect to begin this first-in-human clinical trial later this year.
  • Research and Development (R&D) Expenses – R&D expenses were $15.6 million for the quarter ended June 30, 2023, compared to $18.9 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $19.8 million for the quarter ended June 30, 2023, compared to $23.1 million for the same quarter in 2022.

EQS-News: Apogenix AG: Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model

Retrieved on: 
Friday, June 2, 2023
Tumor-associated macrophage, Drug development, University, Frontiers, Tams, Doctor of Philosophy, HERA, Radiation, Patient, Immune system, CD40, TME, TNFRSF, CD40L, Tumor microenvironment, Prostate cancer, Pharmaceutical industry, Vaccine, Immunology

In the studies, Apogenix, in collaboration with the group from Professor Tim Illidge at the University of Manchester, UK, demonstrated the therapeutic benefits of the hexavalent CD40 agonist HERA-CD40L in models of prostate cancer refractory to anti-PD-1 therapies, both as monotherapy and in combination with radiotherapy.

Key Points: 
  • In the studies, Apogenix, in collaboration with the group from Professor Tim Illidge at the University of Manchester, UK, demonstrated the therapeutic benefits of the hexavalent CD40 agonist HERA-CD40L in models of prostate cancer refractory to anti-PD-1 therapies, both as monotherapy and in combination with radiotherapy.
  • Thomas Hoeger, PhD, CEO of Apogenix, said: “Immune checkpoint inhibitors have revolutionized cancer treatment, however, the overall response rate for all cancer types in patients is still below twenty percent.
  • HERA-CD40L is a novel molecule from Apogenix’ platform of hexavalent Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonists.
  • Due to its characteristic of bridging the transition from innate immunity to the initiation of adaptive immunity, CD40 represents a very attractive target for drug development.

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 11, 2023
Memorial Sloan Kettering Cancer Center, Tumor-associated macrophage, Operation, AACR, Roche, Cancer, G&A, Tams, Bolt, ASCO, ISAC, Investigational New Drug, American Society of Clinical Oncology, Data, Patient, Administration, Annual general meeting, MSK, BMS, Research and development, Cytokine, Chemokine, PD-1, Research, Breast cancer, MPH, R, Society, IND, Disease, Safety, Pharmaceutical innovations, Nivolumab, Pharmaceutical industry, Fine chemical, Doctor of Philosophy

New BDC-3042 data presented at the 2023 American Association of Cancer Research (AACR) Annual Meeting in April 2023 in Orlando, Florida.

Key Points: 
  • New BDC-3042 data presented at the 2023 American Association of Cancer Research (AACR) Annual Meeting in April 2023 in Orlando, Florida.
  • Collaboration Revenue – Collaboration revenue was $1.8 million and $0.8 million for the quarter ended March 31, 2023, and 2022, respectively.
  • General and Administrative (G&A) Expenses – G&A expenses were $5.6 million for the quarter ended March 31, 2023, compared to $6.3 million for the same quarter in 2022.
  • Loss from Operations – Loss from operations was $18.4 million for the quarter ended March 31, 2023, compared to $23.9 million for the same quarter in 2022.